Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSCs for ARDS in Malignancy Patients
NCT02804945Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2017
- Primary completion
- Jun 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mesenchymal stem cells in acute respiratory distress syndrome (ARDS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Adverse Events of Participants Treated with Allogeneic Human Mesenchymal Stem Cells at 30 days. Started Feb 2017; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT02804945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02804945.